Corpus Intelligence IC Memo — PARK CITY HOSPITAL 2026-04-26 04:03 UTC
IC Memo — PARK CITY HOSPITAL
Investment Committee Memorandum | UT | 37 beds | Grade B | EBITDA uplift $8.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PARK CITY HOSPITAL

CCN 460057 | SUMMIT, UT | 37 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

PARK CITY HOSPITAL is a 37-bed suburban community hospital in SUMMIT, UT with $120.8M in net patient revenue and a 13.7% operating margin. The hospital serves a payer mix of 20.4% Medicare, 8.8% Medicaid, and 70.8% commercial.

Thesis: Turnaround. Our ML models identify $8.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.7% to 21.1% (+736bps).

Net Revenue HCRIS$120.8M
Current EBITDA COMPUTED$16.6M
Operating Margin COMPUTED13.7%
Occupancy HCRIS26.3%
Revenue / Bed COMPUTED$3.3M
Net-to-Gross HCRIS57.4%
Distress Probability ML54.3%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
26
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 13.7% places it above the state median. Among 26 size-comparable peers (18-74 beds), the median margin is 3.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (18-74), prioritizing same-state peers. 26 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PARK CITY HOSPITAL (Target)UT37$120.8M13.7%
CEDAR CITY HOSPITALUT48$136.8M31.4%
LONE PEAK HOSPITALUT61$133.1M25.2%
ALTA VIEW HOSPITALUT57$130.9M-0.6%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
LAYTON HOSPITALUT37$121.1M9.5%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%
THE ORTHOPEDIC SPECIALTY HOSPIUT40$88.7M12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.5M+210bp18mo
Cost to Collect4.5%2.5%$2.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.5M+122bp9mo
Clean Claim Rate88.0%96.0%$77K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.5M
Cost to Collect
$2.4M
Denial Rate Reduction
$2.4M
A/R Days Reduction
$1.5M
Clean Claim Rate
$77K
Total EBITDA Uplift$8.9M
Current EBITDA$16.6M
+ RCM Uplift+$8.9M
Pro Forma EBITDA$25.4M
Current Margin13.7%
Pro Forma Margin21.1%
WC Released (1x)$4.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$25.5M$198.1M7.78x50.7%
Base (11x exit)10.0x11.0x$25.5M$226.2M8.88x54.8%
Bull Case9.0x11.0x$22.9M$263.8M11.51x63.0%
Bull (12x exit)9.0x12.0x$22.9M$294.5M12.85x66.6%
Bear Case11.0x10.0x$28.0M$145.4M5.19x39.0%
Bear (11x exit)11.0x11.0x$28.0M$169.0M6.03x43.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 26.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 26 hospitals with 18-74 beds
  • Same-state prioritization (n=27)
  • Comp margins: P25=-12.8% / P50=3.0% / P75=13.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.